Vermont senators, physicians urge passage of S.28 to expand telemedicine abortion access and shield providers' contact information

Senator Ginny Lyons, chair of the Vermont Senate Health & Welfare Committee, and other committee members convened a public briefing where physicians described how S.28 would change telemedicine abortion care and protect providers from third‑party intrusion.

The panel focused on two provisions in S.28: allowing providers to prescribe medication abortion after a standardized questionnaire (rather than requiring a prior in‑person or video visit) and removing practitioners’ private telephone numbers and addresses from broadly accessible public listings. The senators said the bill has cleared the Senate Health & Welfare Committee and been sent to the House for further consideration.

The discussion matters because speakers said the changes would expand access to evidence‑based medication abortion care while reducing risks to clinicians. “These pills are really safe,” said Dr. Linda Prine, professor of family and community medicine at the Icahn School of Medicine at Mount Sinai and co‑founder of the Reproductive Health Access Project. Prine described decades of research on mifepristone and misoprostol and said remote protocols have proven safe in clinical studies and during the pandemic when mailing became necessary.

Dr. Renee Johansen, an OB‑GYN and clinical assistant professor at Dartmouth’s Geisel School of Medicine who founded a telehealth clinic providing medication abortion under state shield laws, told the committee the questionnaire workflow is designed to screen for contraindications and to “bump out” patients for further evaluation when answers indicate a potential safety concern. She said providers follow World Health Organization guidance and typically limit mail‑order medication abortion to early gestational ages (the practice described in testimony was constrained to first‑trimester guidelines).

Why the bill: presenters described two practical risks that S.28 seeks to address. First, requiring an in‑person or synchronous video visit, the witnesses said, creates access barriers for people in precarious home situations, minors who cannot safely use video, and others who cannot take time off work. Dr. Johansen said asynchronous, questionnaire‑based prescribing permits people to complete screening on a phone and receive medication quickly. Second, testimony stressed that publishing clinicians’ home addresses and personal phone numbers exposes providers to harassment and legal risk. Senator Lyons said S.28 would keep private contact information off general web pages and limit public listings to work addresses only.

Speakers cited recent legal pressure on clinicians outside Vermont as evidence that statutory protections matter. “One of our doctors has had two charges leveled against her, one by the state of Texas…and the other charge…from Louisiana,” Dr. Prine said, describing criminal prosecutions that followed discovery of pill packaging and publicized provider information. Prine said such prosecutions and the public posting of a clinician’s address led to security threats and costly protective measures. Testimony framed S.28 as part of a broader set of shield laws in New England and other states that enable clinicians to provide medication abortion and follow‑up care by mail and by telehealth.

Panelists described operational details discussed in the committee: many telemedicine providers use a standardized online questionnaire that asks about last menstrual period, medications, medical history and other items needed for safe prescribing. Providers said the questionnaire automatically flags responses that require further assessment (for example, gestational age estimates beyond the provider’s threshold) and triggers direct clinician follow‑up. Witnesses said their organizations generally follow WHO first‑trimester guidance and that pharmacies and mailed supplies now supplement prescribing options.

Cost and navigation: Dr. Prine told the committee that many shield‑law providers charge a sliding fee (she cited a typical charge of $150, with sliding scales down to zero) and said her teams never refuse care because a patient cannot pay. Panelists also described a volunteer‑run miscarriage and abortion hotline that fields medical and logistics calls; the hotline operates long daily hours to support patients who received medications by mail or elsewhere.

Legal risks and federal questions: witnesses warned about two federal threats: potential rollbacks to FDA policies governing mifepristone and application of the 19th‑century Comstock Act (anti‑obscenity statute) to modern distribution of abortion materials. Speakers discussed California legislative language (described in testimony as AB260) and a possible interstate reciprocity approach for shield states to blunt federal or out‑of‑state enforcement. Senator Lyons emphasized Vermont’s constitutional reproductive liberty amendment (Article 22) as a foundational protection and urged statutory clarifications to reinforce prescribing and licensure authority.

Committee questions and public comment: Representative Molly Burke asked about the legal landscape for prescribing to patients in states without shield laws; panelists said criminal exposure is a concern for providers who act from non‑shield states and described work on interstate agreements to protect clinician licensure and practice. Jessica Garner of the Vermont Medical Society asked about travel and safety for clinicians; witnesses said shield‑law providers avoid travel to non‑shield states and support reciprocal protections among shield states.

Witnesses recommended steps for Vermonters who want to support telemedicine access: volunteers for 24/7 hotlines and logistics teams, donations to reproductive health organizations, and public education about what shield laws do and do not change. Several lawmakers closed by urging civic engagement and by noting the continuing legislative and courtroom developments that could affect access nationally.

The committee continues to consider S.28 in the House; no House action was recorded during the briefing.